Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by mcarter4on Dec 10, 2003 1:20pm
289 Views
Post# 6764311

RE: ONC Coverage: Toronto star today

RE: ONC Coverage: Toronto star today<> Having never used the calculator as I never really believed it would give useful answers, cranking out NRM at $1100 US would seem to confirm my suspicions. <> The science seems to be real, all it will take is for exec. mngt. to develop a credible BPlan and deliver (which based on things to date may be a momentous task).
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities

Stockhouse Logo
Support
Legal
Follow Us
Stockhouse.com is owned by Stockhouse Publishing Ltd. © 2019 Stockhouse Publishing Ltd. All rights reserved. Financial Market Data powered by Refinitiv. All rights reserved. Quotes and other data delayed by 15 minutes for NYSE/AMEX/NASDAQ, 20 minutes for TSX/TSX-V unless otherwise indicated. Google Play and the Google Play logo are trademarks of Google Inc. The Apple logo and iTunes are trademarks of Apple Inc., registered in the U.S. and other countries.